Gonadotropin releasing hormone agonist and levonorgestrel-intrauterine device followed by in vitro fertilization program as management strategy for an infertile endometrial cancer patient: A case report

Giuseppe Nucera, Vincenzo Dario Mandato, Maria Carolina Gelli, Stefano Palomba, Giovanni Battista La Sala

Research output: Contribution to journalArticle

Abstract

Background: A progressive delay in the age of first conception results in an increased frequency of endometrial cancer patients in reproductive age and desiring childbearing. Case: A 38-year-old infertile woman with stage I endometrioid adenocarcinoma was treated with gonadotropin releasing hormone agonist (GnRHa) and levonorgestrel-releasing intrauterine device (LNG-IUD). After disease remission, she underwent a controlled ovarian stimulation for standard in vitro fertilization (IVF) program and had a pregnancy delivering a healthy male baby. Total laparoscopic hysterectomy with bilateral salpingo-oophorectomy was performed four months after delivery. The patient is free of disease after 3-year follow-up. Conclusion: GnRHa plus LNG-IUD followed by IVF program is a safe and effective fertility-sparing strategy to manage infertile patients with stage I endometrial cancer.

Original languageEnglish
Pages (from-to)219-221
Number of pages3
JournalGynecological Endocrinology
Volume29
Issue number3
DOIs
Publication statusPublished - Mar 2013

Keywords

  • Endometrial cancer
  • Fertility
  • GnRH-a
  • IVF
  • LNG-IUD

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'Gonadotropin releasing hormone agonist and levonorgestrel-intrauterine device followed by in vitro fertilization program as management strategy for an infertile endometrial cancer patient: A case report'. Together they form a unique fingerprint.

  • Cite this